Clinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strains

Award NoticeNo Set AsideAwarded

This federal contract opportunity has been awarded to on July 25, 2025.

Award Information

This solicitation resulted in an award to for approximately $98,593,151 on July 25, 2025. Similar contracts are typically issued by HEALTH AND HUMAN SERVICES, DEPARTMENT OF under 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Award Number: 75A50125C00008
Award Amount: $98,593,151
Award Date: July 25, 2025

View full award details on USASpending.gov

Key Takeaways

No response deadline specified - contact the agency for details
Set-aside for No Set Aside businesses
Work to be performed in Washington, DC
Industry: Research and Development in Biotechnology (except Nanobiotechnology)

Contract Details

Notice ID: 75A50125C00008
Opportunity Type: Award Notice
Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-Agency: OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office: ASPR ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE
Posted Date: Tuesday, October 14, 2025
Response Deadline: Not specified
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
PSC Code: AN11
Set-Aside: No Set Aside
Place of Performance: Washington, DC, 20201
Status: Active

View on SAM.gov

Description

No description available. View the full opportunity on SAM.gov for complete details.

Why This Opportunity Matters

HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking responses for research and development in biotechnology (except nanobiotechnology) with a set-aside for No Set Aside businesses in Washington, DC. This set-aside designation means eligible businesses face reduced competition from larger firms.

Clinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strains

Award Information

Key Takeaways

Contract Details

Description

Why This Opportunity Matters

Similar Opportunities

AJ11-VA Depleted Uranium Program PO 512C50314

Q-RNAscope In-House Assay

Low-cost, Connected, Digital Lateral Flow Platform to Detect Influenza A, Influenza B, and SARS-Cov -2 for use in Over-the-Counter (OTC) Settings

A-High Throughput Transcriptomics (HTTr)

human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)

Browse Related